āĻšā§āĻŽGRF âĸ BME
add
Grifols SA Class A
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§Ž.ā§Šā§ĢâŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
ā§Ž.ā§§ā§ŦâŦ - ā§Ž.ā§Šā§§âŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
ā§.ā§Šā§¨âŦ - ā§§ā§§.ā§Šā§ĢâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§Ģā§Ļā§.ā§Ēā§Ŧ āĻā§ EUR
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
⧧⧍.ā§ā§ŽÂ āϞāĻž
P/E āĻ
āύā§āĻĒāĻžāϤ
ā§Šā§Ģ.ā§Šā§¯
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
BME
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
(EUR) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ⧧⧝ā§.ā§Ģā§ŽÂ āĻā§ | ā§§ā§§.ā§Ŧā§Ŧ% |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§Šā§Ģ.ā§Šā§§Â āĻā§ | ⧍ā§Ļ.ā§Šā§¨% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§Ŧ.⧝ā§Ļ āĻā§ | ā§ā§Ŧ.ā§Žā§Ŧ% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | ā§Š.ā§Ē⧝ | ā§Ģā§Ž.ā§Ŧā§Ē% |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | â | â |
EBITDA | ā§Ē⧝.ā§Ģā§Â āĻā§ | -ā§§ā§§.ā§Ē⧝% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | ā§Ŧā§Ļ.⧍ā§Ļ% | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(EUR) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ā§§ā§Ļā§Ļ.ā§Ēā§Ļ āĻā§ | ā§Ģā§Ģ.ā§Ēā§Ļ% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ⧍⧧.ā§Ēā§§āĻļāĻ¤Â āĻā§ | ā§§.⧝ā§% |
āĻŽā§āĻ āĻĻāĻžā§ | ⧧⧍.ā§Žā§ĻāĻļāĻ¤Â āĻā§ | -ā§Ģ.ā§Ļā§Ģ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Žā§Ŧā§Ļ.ā§ā§Ļ āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§Ŧā§Ž.ā§Ļā§Ē āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§Ļ.⧝⧠| â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§Ģ.ā§Ļā§Ž% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | ā§Ģ.ā§ā§¯% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
(EUR) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§Ŧ.⧝ā§Ļ āĻā§ | ā§ā§Ŧ.ā§Žā§Ŧ% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | ā§Ģā§§.ā§Ēā§Ŧ āĻā§ | ⧍ā§Ļā§Ž.ā§Ģā§Ē% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§§ā§.ā§Žā§ŠÂ āĻā§ | -ā§¨ā§Ž.ā§Šā§§% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -⧍.ā§ā§¨Â āĻā§ | -ā§§ā§Žā§Ģ.ā§Ļā§Ž% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | ā§Šā§Š.ā§Ēā§ŽÂ āĻā§ | ā§Ŧā§Ģā§Ž.ā§Žā§% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| ā§§ā§Ŧ.⧍ā§Ē āĻā§ | ā§§ā§¨ā§Š.ā§Ģā§Ŧ% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasmaâbased products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
āϏāĻŋāĻāĻ
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
ā§§ā§Ž āύāĻā§, ⧧⧝ā§Ēā§Ļ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§¨ā§Š,ā§Žā§Šā§Š